1. A Retrospective Analysis of Treatment Outcomes in Adult T Cell Leukemia/Lymphoma Patients with Aggressive Disease Treated with or without Allogeneic Stem Cell Transplantation: A Single-Center Experience 
Hideaki Kawada, Makoto Yoshimitsu, Daisuke Nakamura, Akihiko Arai, Maiko Hayashida, Yuhei Kamada, Kenichi Maekawa, Satoshi Fujino, Mamiko Arima, Naosuke Arima, Tomohisa Tabuchi, Hirosaka Inoue, Heiichiro Hamda, Shinsuke Suzuki, Kakushi Matsushita, Naomichi Arima 
Biology of Blood and Marrow Transplantation 
Volume 21, Issue 4, Pages (April 2015)
DOI: /j.bbmt
Copyright © 2015 American Society for Blood and Marrow Transplantation Terms and Conditions

2. Figure 1
Flowchart of study inclusion of ATL patients who received only chemotherapy or allo-HSCT.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2015 American Society for Blood and Marrow Transplantation Terms and Conditions

3. Figure 2
(A) OS after the first chemotherapy in patients with ATL. (B) OS in patients receiving either HSCT or chemotherapy only.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2015 American Society for Blood and Marrow Transplantation Terms and Conditions

4. Figure 3
(A) OS according to sIL-2R levels in patients with ATL. (B) OS after HSCT, according to disease status (PD versus non-PD at HSCT).
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2015 American Society for Blood and Marrow Transplantation Terms and Conditions

5. Figure 4
(A) OS according to sIL-2R < 2000 U/ml for >3 months in patients with ATL receiving only chemotherapy. (B) OS in chemosensitive patients with or without HSCT.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2015 American Society for Blood and Marrow Transplantation Terms and Conditions